Quantinno Capital Management LP Has $1.86 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Quantinno Capital Management LP boosted its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 65.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,612 shares of the medical device company’s stock after purchasing an additional 20,467 shares during the period. Quantinno Capital Management LP owned about 0.08% of Tandem Diabetes Care worth $1,859,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. AlphaQuest LLC raised its holdings in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after buying an additional 541 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after buying an additional 748 shares in the last quarter. Assetmark Inc. grew its position in Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 535 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after acquiring an additional 1,101 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its stake in Tandem Diabetes Care by 5,955.9% during the fourth quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock worth $74,000 after acquiring an additional 2,025 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently weighed in on TNDM. Stifel Nicolaus reduced their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Mizuho initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a “neutral” rating and a $20.00 price objective for the company. Piper Sandler decreased their target price on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Barclays lowered their price target on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.81.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock opened at $21.65 on Thursday. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -11.22 and a beta of 1.47. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The company’s fifty day moving average is $19.36 and its 200 day moving average is $27.68. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company’s quarterly revenue was up 22.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.65) EPS. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.90% of the stock is owned by insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.